New drugs for medullary thyroid cancer: new promises?

Abstract:

:Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a hereditary form based on germline RET mutations in approximately one-third of cases. Historically, patients with advanced, metastasized MTC have had a poor prognosis, partly due to limited response to conventional chemotherapy and radiation therapy. In the past decade, however, considerable progress has been made in identifying key genetic alterations and dysregulated signaling pathways paving the way for the evaluation of a series of multitargeted kinase inhibitors that have started to meaningfully impact clinical practice. Two drugs, vandetanib and cabozantinib, are now approved in the US and EU for use in advanced, progressive MTC, with additional targeted agents also showing promise or awaiting results from clinical trials. However, the potential for toxicities with significant reduction in quality of life and lack of curative outcomes has to be carefully weighed against potential for benefit. Despite significant PFS prolongation observed in randomized clinical trials, most patients even with metastatic disease enjoy indolent courses with slow progression observed over years, wherein watchful waiting is still the preferred strategy. As advanced, progressive MTC is a rare and complex disease, a multidisciplinary approach centered in specialized centers providing interdisciplinary expertise in the individualization of available therapeutic options is preferred. In this review, we summarize current concepts of the molecular pathogenesis of advanced MTC and discuss results from clinical trials of targeted agents and also cytotoxic chemotherapy in the context of clinical implications and future perspectives.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Spitzweg C,Morris JC,Bible KC

doi

10.1530/ERC-16-0104

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

R287-97

issue

6

eissn

1351-0088

issn

1479-6821

pii

ERC-16-0104

journal_volume

23

pub_type

杂志文章,评审
  • 65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma.

    abstract::Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-18-0085

    authors: Neumann HP,Young WF Jr,Krauss T,Bayley JP,Schiavi F,Opocher G,Boedeker CC,Tirosh A,Castinetti F,Ruf J,Beltsevich D,Walz M,Groeben HT,von Dobschuetz E,Gimm O,Wohllk N,Pfeifer M,Lourenço DM Jr,Peczkowska M,Patocs A,

    更新日期:2018-08-01 00:00:00

  • Role of chromosomal instability in cancer progression.

    abstract::Cancer cells often display chromosomal instability (CIN), a defect that involves loss or rearrangement of the cell's genetic material - chromosomes - during cell division. This process results in the generation of aneuploidy, a deviation from the haploid number of chromosomes, and structural alterations of chromosomes...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0187

    authors: McClelland SE

    更新日期:2017-09-01 00:00:00

  • Epigenetic regulation by the menin pathway.

    abstract::There is a trend of increasing prevalence of neuroendocrine tumors (NETs), and the inherited multiple endocrine neoplasia type 1 (MEN1) syndrome serves as a genetic model to investigate how NETs develop and the underlying mechanisms. Menin, encoded by the MEN1 gene, at least partly acts as a scaffold protein by intera...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0298

    authors: Feng Z,Ma J,Hua X

    更新日期:2017-10-01 00:00:00

  • Peroxisome proliferator-activated receptor gamma and BRCA1.

    abstract::Peroxisome proliferator-activated receptor gamma agonists have been proposed as breast cancer preventives. Individuals who carry a mutated copy of BRCA1, DNA repair-associated gene, are at increased risk for development of breast cancer. Published data in the field suggest there could be interactions between peroxisom...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-18-0449

    authors: Furth PA

    更新日期:2019-02-01 00:00:00

  • RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).

    abstract::Medullary thyroid carcinomas (MTC) arise from thyroid parafollicular, calcitonin-producing C-cells and can occur either as sporadic or as hereditary diseases in the context of familial syndromes, including multiple endocrine neoplasia 2A (MEN2A), multiple endocrine neoplasia 2B (MEN2B) and familial MTC (FMTC). In a la...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0303

    authors: Castellone MD,Melillo RM

    更新日期:2018-02-01 00:00:00

  • Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.

    abstract::Hormonal therapy leads to improved survival in oestrogen receptor (ER) positive early breast cancer and long-term responses in advanced disease. However, resistance to such therapy is a serious clinical problem. This article considers the data for and against there being a significant role for the oncogene HER-2 in su...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0080191

    authors: Dowsett M

    更新日期:2001-09-01 00:00:00

  • Human melanoma cells express functional receptors for thyroid-stimulating hormone.

    abstract::We have reported a high prevalence of hypothyroidism in the cutaneous melanoma population, suggesting that the pathologic hormonal environment of hypothyroidism promotes melanoma growth. The objective of this study was to test the hypothesis that TSH, which circulates at elevated levels in hypothyroid individuals, sti...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01239

    authors: Ellerhorst JA,Sendi-Naderi A,Johnson MK,Cooke CP,Dang SM,Diwan AH

    更新日期:2006-12-01 00:00:00

  • Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line.

    abstract::This study analyzes the uptake and antiproliferative effect of two different chemical forms of iodine, iodide (I-) and molecular iodine (I2), in MCF-7 cells, which are inducible for the Na+/I- symporter (NIS) and positive for pendrin (PDS). The mouse fibroblast cell line NIH3T3 was used as control. Our results show th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01250

    authors: Arroyo-Helguera O,Anguiano B,Delgado G,Aceves C

    更新日期:2006-12-01 00:00:00

  • Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.

    abstract::We studied the psychological performance and the quality of life in patients with differentiated thyroid carcinoma, either during treatment with chronic suppressive doses of levothyroxine, or during the withdrawal of levothyroxine needed to perform whole-body scanning with radioactive iodine, with those of appropriate...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0100601

    authors: Botella-Carretero JI,Galán JM,Caballero C,Sancho J,Escobar-Morreale HF

    更新日期:2003-12-01 00:00:00

  • Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.

    abstract::Numerous epidemiological observations point to sex differences in lung cancer etiology and progression. The present study was aimed at understanding the bases of these sex differences. To test the effect of estradiol on tumor progression, we used a mouse model based on conditional Kras expression and concurrent deleti...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0002

    authors: Hammoud Z,Tan B,Badve S,Bigsby RM

    更新日期:2008-06-01 00:00:00

  • LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity.

    abstract::Platinum-based therapy remains the cornerstone for cancer therapy; however, its efficacy varies. The role of lipoprotein receptor-mediated lipid entry for cancer development has been reported. Yet, the roles and mechanism of the low-density lipoprotein receptor (LDLR) in chemo-sensitivities are unknown. In the current...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0095

    authors: Chang WC,Wang HC,Cheng WC,Yang JC,Chung WM,Ho YP,Chen L,Hung YC,Ma WL

    更新日期:2020-02-01 00:00:00

  • Endothelins and hypoxia-inducible factor in cancer.

    abstract::The endothelin system is a family of three similar small peptides, two G-protein-coupled receptors and two proteinases. Endothelins have several physiological roles, notably in embryonic differentiation and vascular homeostasis. Numerous types of tumour express endothelins and their regulation is often aberrant when c...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0057

    authors: Grimshaw MJ

    更新日期:2007-06-01 00:00:00

  • Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.

    abstract::Insulinomas are rare endocrine neoplasias that constitute the most frequent islet cell tumours. Somatostatin (SST) analogs are tentatively used to inhibit insulin secretion and control tumour growth in patients with local invasion or inoperative metastasis, but variable responses have been reported. Data regarding som...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.00962

    authors: de Sá SV,Corrêa-Giannella ML,Machado MC,de Souza JJ,Pereira MA,Patzina RA,Siqueira SA,Machado MC,Giannella-Neto D

    更新日期:2006-03-01 00:00:00

  • Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.

    abstract::The prognosis remains ill-defined in patients with liver metastases of well-differentiated (WD) digestive endocrine carcinomas (DEC) with high Ki-67 index. The objectives of this study were to determine whether Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0319

    authors: Hentic O,Couvelard A,Rebours V,Zappa M,Dokmak S,Hammel P,Maire F,O'Toole D,Lévy P,Sauvanet A,Ruszniewski P

    更新日期:2010-12-13 00:00:00

  • Treatment of refractory thyroid cancer.

    abstract::Distant metastases from thyroid cancer of follicular origin are uncommon. Treatment includes levothyroxine administration, focal treatment modalities with surgery, external radiation therapy and thermal ablation, and radioiodine in patients with uptake of 131I in their metastases. Two-thirds of distant metastases beco...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0542

    authors: Berdelou A,Lamartina L,Klain M,Leboulleux S,Schlumberger M

    更新日期:2018-04-01 00:00:00

  • Role of hypoxia-inducible factor-1alpha as a cancer therapy target.

    abstract::Hypoxia occurs in solid tumours due to a mismatch between tumour growth and angiogenesis. Hypoxia in solid tumours is associated with an aggressive phenotype and resistance to radiation therapy and chemotherapy leading to poor patient prognosis. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor, which is ac...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01290

    authors: Patiar S,Harris AL

    更新日期:2006-12-01 00:00:00

  • The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

    abstract::Ovarian cancer remains one of the leading causes of cancer deaths. Thus, new biomarkers predictive of response to the standard paclitaxel-carboplatin treatment are needed to improve chemotherapy strategies. MicroRNAs have the potential to modify drug outcomes. Based on this, we have demonstrated in this study that pat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-10-0148

    authors: Leskelä S,Leandro-García LJ,Mendiola M,Barriuso J,Inglada-Pérez L,Muñoz I,Martínez-Delgado B,Redondo A,de Santiago J,Robledo M,Hardisson D,Rodríguez-Antona C

    更新日期:2010-12-21 00:00:00

  • Surgery for midgut carcinoid.

    abstract::Many clinicians prefer to avoid surgery in patients with carcinoid neoplasia, because of its slow growth and relatively favourable prognosis. Nevertheless, the commonest cause of death in patients with carcinoid is advanced metastatic disease, and both clinical and epidemiological data indicate that the more effective...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0100469

    authors: Sutton R,Doran HE,Williams EM,Vora J,Vinjamuri S,Evans J,Campbell F,Raraty MG,Ghaneh P,Hartley M,Poston GJ,Neoptolemos JP

    更新日期:2003-12-01 00:00:00

  • Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma.

    abstract::Ten to fifteen percent of fine-needle aspiration biopsy (FNAB) of thyroid nodules are indeterminate. Galectin-3 (Gal-3) and the oncogene BRAFV600E are markers of malignancy useful to improve FNAB accuracy. The objective of this study was to determine whether the combined analysis of Gal-3 and BRAFV600E expression in t...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-07-0147

    authors: Sapio MR,Guerra A,Posca D,Limone PP,Deandrea M,Motta M,Troncone G,Caleo A,Vallefuoco P,Rossi G,Fenzi G,Vitale M

    更新日期:2007-12-01 00:00:00

  • lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling.

    abstract::Pancreatic neuroendocrine neoplasms (pNENs) are endocrine tumors arising in pancreas and is the most common neuroendocrine tumors. Mounting evidence indicates lncRNA H19 could be a determinant of tumor progression. However, the expression and mechanism of H19 and the relevant genes mediated by H19 in pNENs remain unde...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0552

    authors: Ji M,Yao Y,Liu A,Shi L,Chen D,Tang L,Yang G,Liang X,Peng J,Shao C

    更新日期:2019-07-01 00:00:00

  • Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study.

    abstract::The study aims to examine whether the annual variations in fasting plasma glucose (FPG) measurements, represented by the coefficient of variation (CV), predict cancer incidence and mortality in the subsequent years independent of traditional risk factors of type 2 diabetic patients. A computerized database of patients...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-12-0038

    authors: Lin CC,Li CI,Liu CS,Lin WY,Chen CC,Yang SY,Lee CC,Li TC

    更新日期:2012-07-18 00:00:00

  • Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.

    abstract::Previous SNP array analyses have revealed genomic alterations of the Notch pathway as being the most frequent abnormality in adrenocortical tumors (ACTs). The aim of the present study was to evaluate the expression of components of Notch signaling in ACTs and to correlate them with clinical outcome. The mRNA expressio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0163

    authors: Ronchi CL,Sbiera S,Altieri B,Steinhauer S,Wild V,Bekteshi M,Kroiss M,Fassnacht M,Allolio B

    更新日期:2015-08-01 00:00:00

  • 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

    abstract::177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncomm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0509

    authors: Hofving T,Sandblom V,Arvidsson Y,Shubbar E,Altiparmak G,Swanpalmer J,Almobarak B,Elf AK,Johanson V,Elias E,Kristiansson E,Forssell-Aronsson E,Nilsson O

    更新日期:2019-04-01 00:00:00

  • Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.

    abstract::Obesity increases both the risk and mortality associated with many types of cancer including that of the breast. In mice, obesity increases both incidence of spontaneous tumors and burden of transplanted tumors. Our findings identify leptin, an adipose secreted cytokine, in promoting increased mammary tumor burden in ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0102

    authors: Zheng Q,Dunlap SM,Zhu J,Downs-Kelly E,Rich J,Hursting SD,Berger NA,Reizes O

    更新日期:2011-07-11 00:00:00

  • The optimal imaging of adrenal tumours: a comparison of different methods.

    abstract::Computed tomography (CT; unenhanced, followed by contrast-enhanced examinations) is the cornerstone of imaging of adrenal tumours. Attenuation values of <10 Hounsfield units on an unenhanced CT are practically diagnostic for adenomas. When lesions cannot be characterised adequately with CT, magnetic resonance imaging ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0045

    authors: Ilias I,Sahdev A,Reznek RH,Grossman AB,Pacak K

    更新日期:2007-09-01 00:00:00

  • Sporadic hypercalcitoninemia: clinical and therapeutic consequences.

    abstract::'Calcitonin screening' is not accepted as the standard of care in daily practice. The clinical and surgical consequences of 'calcitonin screening' in a series of patients with mildly elevated basal calcitonin and pentagastrin stimulated calcitonin levels are presented. 260 patients with elevated basal (>10 pg/ml) and ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0059

    authors: Scheuba C,Kaserer K,Moritz A,Drosten R,Vierhapper H,Bieglmayer C,Haas OA,Niederle B

    更新日期:2009-03-01 00:00:00

  • Obesity and cancer: mechanistic insights from transdisciplinary studies.

    abstract::Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for an association between obesity and increased risk of breast and prostate cancer incidence and mortality. Moreover, we describe dat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0400

    authors: Allott EH,Hursting SD

    更新日期:2015-12-01 00:00:00

  • Thyrotoxicosis with concomitant thyroid cancer.

    abstract::Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0129

    authors: Fu H,Cheng L,Jin Y,Chen L

    更新日期:2019-07-01 00:00:00

  • Acquired resistance to aromatase inhibitors: where we stand!

    abstract::Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen receptor-positive (ER+) breast cancer in postmenopausal women. They block estrogen biosynthesis through aromatase inhibition, thus preventing tumour progression. Besides the therapeutic success of the third-generation AIs, acquired...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0425

    authors: Augusto TV,Correia-da-Silva G,Rodrigues CMP,Teixeira N,Amaral C

    更新日期:2018-05-01 00:00:00

  • Genomic classification of benign adrenocortical lesions.

    abstract::Benign adrenal tumors cover a spectrum of lesions with distinct morphology and steroid secretion. Current classification is empirical. Beyond a few driver mutations, pathophysiology is not well understood. Here, a pangenomic characterization of benign adrenocortical tumors is proposed, aiming at unbiased classificatio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0128

    authors: Faillot S,Foulonneau T,Néou M,Espiard S,Garinet S,Vaczlavik A,Jouinot A,Rondof W,Septier A,Drougat L,Hécale-Perlemoine K,Ragazzon B,Rizk-Rabin M,Sibony M,Bonnet-Serrano F,Guibourdenche J,Libé R,Groussin L,Dousset B,

    更新日期:2021-01-01 00:00:00